Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 12:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,846 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dexamethasone/Dexamethasone acetate Clear all
Completed Phase 2 Interventional

Dexamethasone Iontophoretic Patch for the Treatment of Pain Associated With Lateral Epicondylitis

NCT00794976
View directory record Official record
Conditions
Lateral Epicondylitis, (Tennis Elbow)
Interventions
Dexamethasone Iontophoretic Patch (low dose), Dexamethasone Iontophoretic Patch (high dose), Dexamethasone Passive Patch, Placebo Patch
Drug
Lead sponsor
Travanti Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Oct 7, 2026, 12:20 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study of VLX1570 and Dexamethasone in Myeloma Patients

NCT02372240
View directory record Official record
Conditions
Multiple Myeloma
Interventions
VLX1570 and dexamethasone
Drug
Lead sponsor
Vivolux AB
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 7, 2026, 12:20 AM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Daratumumab, Bortezomib, Iberdomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
43
States / cities
Hot Springs, Arkansas • Cerritos, California • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 7, 2026, 12:20 AM EDT
Terminated Not applicable Interventional

The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer

NCT00000723
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, HIV Infections
Interventions
Methotrexate, Leucovorin calcium, Zidovudine, Dexamethasone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 7, 2026, 12:20 AM EDT
Enrolling by invitation Phase 2 Interventional

DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury

NCT07567274
View directory record Official record
Conditions
Tinnitus
Interventions
DMSO-based otic solution with betahistine, dexamethasone, and lidocaine, DMSO-based transdermal cream with levocarnitine and N-acetylcysteine
Drug
Lead sponsor
Leading Edge Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 4 Interventional Results available

Study of the Effectiveness of Ozurdex for the Control of Uveitis

NCT02049476
View directory record Official record
Conditions
Uveitis, Intermediate, Uveitis, Posterior
Interventions
Dexamethasone pellet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 1 Interventional

Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies

NCT01900509
View directory record Official record
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Acute Leukemia
Interventions
Bendamustine, Clofarabine, Etoposide, Etoposide phosphate, Dexamethasone
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 7, 2026, 12:20 AM EDT
Terminated Phase 4 Interventional

Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease

NCT04413253
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Lifitegrast 5% Ophthalmic Solution, Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution
Drug
Lead sponsor
Eye Surgeons of Indiana
Network
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 7, 2026, 12:20 AM EDT
Terminated Phase 2 Interventional Results available

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

NCT04119336
View directory record Official record
Conditions
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Nivolumab, Ixazomib, Dexamethasone, Cyclophosphamide
Drug
Lead sponsor
Andrew Yee, MD
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Danvers, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 7, 2026, 12:20 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

NCT02297230
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation Therapy (RT), Capecitabine, Trastuzumab, Paclitaxel
Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 7, 2026, 12:20 AM EDT
Terminated Phase 1 Interventional

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT04570631
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Eftozanermin alfa, Bortezomib, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Atlanta, Georgia • Louisville, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 7, 2026, 12:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

NCT04329728
View directory record Official record
Conditions
Lymphoid Malignancies
Interventions
AVM0703
Drug
Lead sponsor
AVM Biotechnology Inc
Industry
Eligibility
12 Years to 95 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Whittier, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 3 Interventional Results available

Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)

NCT00135811
View directory record Official record
Conditions
Glomerulosclerosis, Focal
Interventions
Cyclosporin, Mycophenolate mofetil and Dexamethasone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years to 40 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 7, 2026, 12:20 AM EDT
Terminated Phase 3 Interventional Results available

Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study

NCT03563053
View directory record Official record
Conditions
Ataxia Telangiectasia, Genetic Syndrome
Interventions
EryDex System
Combination Product
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
6 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 7, 2026, 12:20 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer

NCT01607554
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Irinotecan
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 7, 2026, 12:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

NCT05714839
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab, Belantamab mafodotin, Pomalidomide, Dexamethasone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
11
States / cities
Bullhead City, Arizona • Los Angeles, California • Pembroke Pines, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 7, 2026, 12:20 AM EDT
Completed No phase listed Observational

Diagnostic Performance of Screening Tests for Cushing s Syndrome

NCT00361777
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 100 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2019
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 7, 2026, 12:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

NCT04300556
View directory record Official record
Conditions
Solid Tumor
Interventions
Farletuzumab ecteribulin, Prednisone, Prednisolone, Dexamethasone, Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
24
States / cities
Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 7, 2026, 12:20 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Dexamethasone or Clonidine as Adjuncts to Ropivacaine for Caudal Analgesia on Analgesia Duration in Children

NCT02773602
View directory record Official record
Conditions
Postoperative Pain
Interventions
Dexamethasone, Clonidine, Normal Saline
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
6 Months to 6 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 4 Interventional Results available

Community Care for Croup (RCT)

NCT01042145
View directory record Official record
Conditions
Croup
Interventions
Prednisone, Dexamethasone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Year to 8 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 7, 2026, 12:20 AM EDT
Recruiting Phase 2 Interventional

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

NCT04776395
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Dexamethasone, Iberdomide Hydrochloride, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 2 Interventional

SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00006002
View directory record Official record
Conditions
Prostate Cancer
Interventions
dexamethasone, semaxanib
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • Pasadena, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 1 Interventional

Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma

NCT01549431
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Panobinostat, Carfilzomib, Dexamethasone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 2 Interventional Results available

Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

NCT00890656
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide (CTX), Vincristine, Doxorubicin, Decadron, G-CSF, Methotrexate (MTX), Ara-C, Pegaspargase
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 7, 2026, 12:20 AM EDT